Trial reportHeart (British Cardiac Society)2007
Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.
Trial report in Heart (British Cardiac Society), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chinese People's Liberation Army General Hospital
Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.PloS one · 2015Pooled it
- Early Trimetazidine Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Reduces Myocardial Infarction Size.Cardiovascular drugs and therapy · 2023Trial
- Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation.Journal of molecular and cellular cardiology plus · 2025Review
- Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.Indian heart journal · 2018Article
- Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?The open cardiovascular medicine journal · 2018Review
- Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1.British journal of pharmacology · 2016Article
- Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Circulation research · 2014Review
- Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.Cardiology research · 2014Article
- Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Article
- New directions in the treatment of heart failure: targeting free fatty acid oxidation.Current heart failure reports · 2007Review
- Measurement and prevention of myocardial injury during percutaneous coronary intervention.Heart (British Cardiac Society) · 2007Article
- Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.Indian heart journalReview
- Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.American journal of therapeuticsReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of pre-procedural acute oral administration of trimetazidine (TMZ) on percutaneous coronary intervention (PCI)-induced myocardial injury.
designSingle-centre, prospective, randomised evaluation study.
settingPatients with stable angina pectoris and single-vessel disease undergoing PCI. PATIENTS: 582 patients were prospectively randomised. Patients who underwent more than one inflation during PCI were excluded, resulting in 266 patients randomly assigned to 2 groups.
interventionsPatients were randomly assigned to receive or not an acute loading dose of 60 mg of TMZ prior to intervention. MAIN OUTCOME: The frequency and the increase in the level of cardiac troponin Ic (cTnI) after successful PCI. cTnI levels were measured before and 6, 12, 18 and 24 h after PCI.
results136 patients were assigned to the TMZ group and 130 to the control group. Although no statistically significant difference was observed in the frequency of cTnI increase between the two groups, post-procedural cTnI levels were significantly reduced in the TMZ group at all time points (6 h: mean (SD) 4.2 (0.8) vs 1.7 (0.2), p<0.001; 12 h: 5.5 (1.5) vs 2.3 (0.4), p<0.001; 18 h: 9 (2.3) vs 3 (0.5), p<0.001; and 24 h: 3.2 (1.2) vs 1 (0.5), p<0.001). Moreover, the total amount of cTnI released after PCI, as assessed by the area under the curve of serial measurement, was significantly reduced in the TMZ group (p<0.05).
conclusionPre-procedural acute oral TMZ administration significantly reduces PCI-induced myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.